Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Boehringer Ingelheim Animal Health do Brasil Ltda.
483
•Boehringer Ingelheim Animal Health do Brasil Ltda.•December 13, 2022

FDA 483 - Boehringer Ingelheim Animal Health do Brasil Ltda. - December 13, 2022

View on Dashboard

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Boehringer Ingelheim Animal Health do Brasil Ltda.
Record Details

**FDA 483 Summary: Boehringer Ingelheim Animal Health do Brasil Ltda.**

**Inspection Details:** - **Company:** Boehringer Ingelheim Animal Health do Brasil Ltda. - **Location:** Avenida Doutor Roberto Moreira, 5005, Recanto dos Passaros, Paulinia, CEP 13140-970, Brazil - **Inspection Dates:** December 5-13, 2022 - **Type of Establishment:** Animal Drug Manufacturer

**Key Violations/Issues:** 1. **Quality Control Deficiencies:** - The Quality Unit lacked written procedures and failed to address laboratory errors and equipment malfunctions, leading to a 71% invalidation rate of out-of-specification (OOS) test results from January 2020 to November 2022. Personnel issues contributed to 47% of these errors. - Failure to submit a Field Alert to the FDA for OOS assay results during stability testing of Eqvalan (Ivermectin Paste 3%).

2. **Inadequate Investigation and Documentation:** - Failure to thoroughly investigate and document discrepancies and batch failures. Notably, sterility failures in Ivomec Gold Injectable were invalidated without sufficient evidence or comprehensive root cause analysis. - Assay failures for EQVALAN Oral Paste Syringe were invalidated without adequate investigation, attributing errors to sample preparation by inexperienced analysts without clear evidence.

**Regulatory Framework:** The observations highlight non-compliance with FDA regulations regarding quality control and reporting, specifically under the guidance for reporting OOS results and conducting thorough investigations.

**Required Actions:** - Implement comprehensive written procedures for the Quality Unit. - Conduct thorough investigations into OOS results and sterility failures, ensuring all evidence supports the root cause analysis. - Submit required Field Alerts for OOS results as per FDA guidelines. - Enhance training and oversight of personnel to prevent laboratory errors and ensure adherence to procedures.

These actions are crucial to address

Company
Boehringer Ingelheim Animal Health do Brasil Ltda.
Inspection Date
December 13, 2022
Product Type
Veterinary
Office
Office of Inspections and Investigations
Person
  • Ileana Barreto-Petit
Open in Dashboard

ID · a3e09544-c39f-4fc0-90da-10151fe21655

KeyPedia
Regulatory Data Transformed
Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@globalkeysolutions.net
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.